A Webinar on ISOPP Standards - Oral Anticancer Therapies and Monoclonal Antibodies

This session aims to provide the attendee with an overview of the new standards on oral anticancer therapies and monoclonal antibodies that have been incorporated into the 2022 update of the International Society of Oncology Pharmacy Practitioners (ISOPP) Standards for Safe Handling of Cytotoxics. Oral anticancer therapies include cytotoxic, targeted, and endocrine therapies as well as immunotherapies. These drugs, although administered in outpatient setting, still carry significant risk to the patients and others. The ISOPP standards describe the processes for ensuring the safety of ordering, dispensing, and monitoring of these therapies. Additionally, training and education both for the healthcare team and patient and caregivers are recommended. 

As compared to cytotoxic drugs, there is limited information available to guide evaluation of the potential health hazards of monoclonal antibodies.  The ISOPP standards provide information and direction on the safe handling and administration of monoclonal antibodies.

Learning Objectives

By the end of the webinar (60 minutes), participants were able to:

• Describe the recommended standards for prescription content, dispensing, and monitoring of anticancer therapies
• Outline optimal training and education about oral anticancer therapies for patients, caregivers, and staff
• Describe the evaluation of potential health hazards of monoclonal antibodies
• Outline safe handling and administration standards for monoclonal antibodies